Drugging the Undruggable Ras — Immunotherapy to the Rescue?

Metastatic gastrointestinal cancers that express products of mutant KRAS genes have one of the most dismal outcomes of all solid tumors and present an unsolved problem in cancer medicine. An activating point mutation in one of genes encoding Ras was the first somatic point mutation identified in a human cancer, and its discovery established the role of somatic mutations as the common driver of oncogenesis.1,2 The presence of a T-cell immune infiltrate in surgical specimens at the time of diagnosis is more prognostic of survival than anatomic Dukes staging,3 which suggests that natural immune surveillance can have a powerful . . .